- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00697515
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
May 25, 2021 updated by: Shire
A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
Study Overview
Detailed Description
This study has both an optimization and double-blind period
Study Type
Interventional
Enrollment (Actual)
142
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Clinical Study Centers, LLC
-
-
California
-
Irvine, California, United States, 92612
- University of CA, Irvine Child Development Center
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Vince & Associates Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Center for Psychiatry & Behavioral Medicine, Inc
-
-
Texas
-
Houston, Texas, United States, 77007
- Bayou City Research, Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must be 18-55 years of age, inclusive at the time of consent.
- Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable contraceptive requirements of the protocol.
- Subject meets Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD (diagnostic code 314.00 and 314.01) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria with at least 6 of the 9 subtype criteria met. The Adult ADHD Clinical Diagnostic Scale version 1.2 (ACDS v1.2) will be utilized as the diagnostic tool.
- Subject has a Baseline score of > or equal to 28 using the Adult ADHD-RS with prompts.
- Subject must have a minimum level of intellectual functioning, as determined by an Intelligent Quotient (IQ) score of 80 or above based on the Kaufman Brief Intelligence Test (KBIT).
Exclusion Criteria:
- Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms. Comorbid psychiatric diagnoses will be established by the psychiatric evaluation that includes the Structured Clinical Interview for DSM-IV-TR disorders (SCID-I).
- Subjects who are currently considered a suicide risk, any subject who has previously made a suicide attempt or those who are currently demonstrating active suicidal ideation.
- Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
- Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
- Subject has current abnormal thyroid function, as defined as abnormal Screening thyroid stimulating hormone. Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
- Subject has a history of moderate to severe hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg.
- Subject has a documented allergy, hypersensitivity, or intolerance to amphetamines.
- Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.
- Subject has glaucoma.
- Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors (during or within 14 days of test or reference product administration). Stable use of bronchodilator inhalers is not exclusionary.
- Subject is female and pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo administered once-daily for one week during the adult workplace environment setting
|
ACTIVE_COMPARATOR: Lisdexamfetamine Dimesylate (LDX, SPD489)
|
oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase
Time Frame: 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.
The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session.
The scores range from 0-800 with higher scores indicating better performance.
|
2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PERMP Total Score by Timepoint in the Crossover Phase
Time Frame: 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.
The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session.
The scores range from 0-800 with higher scores indicating better performance.
|
2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
PERMP Score for the Number of Math Problems Attempted by Timepoint in the Crossover Phase
Time Frame: 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.
The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session.
The scores range from 0-800 with higher scores indicating better performance.
|
2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
PERMP Score for the Number of Math Problems Answered Correctly by Timepoint in the Crossover Phase
Time Frame: 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test.
The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session.
The scores range from 0-800 with higher scores indicating better performance.
|
2, 4, 8, 10, 12 and 14 hours post-dose on Day 7
|
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale With Prompts (ADHD-RS) Total Score at up to 28 Days in the Dose Optimization Phase
Time Frame: Baseline and 7, 14, 21 and 28 days
|
The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
|
Baseline and 7, 14, 21 and 28 days
|
ADHD-RS With Prompts Total Score in the Crossover Phase
Time Frame: 7 days
|
The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
|
7 days
|
Assessment of Clinical Global Impression-Severity of Illness (CGI-S) in the Dose Optimization Phase
Time Frame: Baseline
|
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
|
Baseline
|
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Dose Optimization Phase
Time Frame: 7, 14, 21 and 28 days
|
CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
|
7, 14, 21 and 28 days
|
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Crossover Phase
Time Frame: 7 days
|
CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
|
7 days
|
Change From Baseline in the Brown Attention Deficit Disorder Scale (BADDS) Total Scores at 26 Days in the Dose Optimization Phase
Time Frame: Baseline and 26 days
|
The BADDS assessment consists of 40 items rated on a scale from 0 (never) to 3 (almost daily).
The total score ranges from 0 to 120 with increasing scores indicating more severe impairment.
|
Baseline and 26 days
|
Level of Satisfaction With Study Treatment on Medication Satisfaction Questionnaire (MSQ) in the Dose Optimization Phase
Time Frame: 26 days
|
MSQ is a survey rating the subject's level of satisfaction with the study treatment medication.
|
26 days
|
Change From Baseline in Adult ADHD Impact Module (AIM-A) Question 1 Score at 26 Days in the Dose Optimization Phase
Time Frame: Baseline and 26 days
|
AIM-A is a quality of life instrument.
Question 1 is 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best).
|
Baseline and 26 days
|
Change From Baseline in AIM-A Question 4 Score at 26 Days in the Dose Optimization Phase
Time Frame: Baseline and 26 days
|
AIM-A is a quality of life instrument.
Question 4 is 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?'
This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree).
|
Baseline and 26 days
|
Change From Baseline in Systolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase
Time Frame: Baseline and 7, 14, 21 and 28 days
|
Baseline and 7, 14, 21 and 28 days
|
|
Change From Baseline in Diastolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase
Time Frame: Baseline and 7, 14, 21 and 28 days
|
Baseline and 7, 14, 21 and 28 days
|
|
Change From Baseline in Pulse Rate at Up to 28 Days in the Dose Optimization Phase
Time Frame: Baseline and 7, 14, 21 and 28 days
|
Baseline and 7, 14, 21 and 28 days
|
|
Change From Baseline in Electrocardiogram Results (QTcF Interval) at 7 Days in the Crossover Phase
Time Frame: Baseline and 7 days
|
QTcF is the QT interval using Fridericia's correction formula.
QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval).
The QT interval has to be corrected in order to aid interpretation.
|
Baseline and 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010 Jun 24;6:34. doi: 10.1186/1744-9081-6-34.
- Brams M, Giblin J, Gasior M, Gao J, Wigal T. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Postgrad Med. 2011 May;123(3):99-108. doi: 10.3810/pgm.2011.05.2288.
- Brown TE, Brams M, Gasior M, Adeyi B, Babcock T, Dirks B, Scheckner B, Wigal T. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin. 2011;27 Suppl 2:23-33. doi: 10.1185/03007995.2011.605441.
- Brown TE, Brams M, Gao J, Gasior M, Childress A. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010 Sep;122(5):7-17. doi: 10.3810/pgm.2010.09.2196.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 18, 2008
Primary Completion (ACTUAL)
December 20, 2008
Study Completion (ACTUAL)
December 20, 2008
Study Registration Dates
First Submitted
June 11, 2008
First Submitted That Met QC Criteria
June 13, 2008
First Posted (ESTIMATE)
June 16, 2008
Study Record Updates
Last Update Posted (ACTUAL)
June 9, 2021
Last Update Submitted That Met QC Criteria
May 25, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPD489-316
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
The Hong Kong Polytechnic UniversityRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
VIZO Specs LtdRecruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Florida State UniversityRecruiting
-
Florida International UniversityRecruiting
-
Region Örebro CountyRecruiting
-
Johns Hopkins UniversityWithdrawn
-
Tris Pharma, Inc.Premier Research Group plcCompleted
Clinical Trials on LDX
-
Dompé Farmaceutici S.p.ACompleted
-
Dompé Farmaceutici S.p.ATerminatedNew-onset Type 1 DiabetesUnited States, Belgium, Georgia, Germany, Italy, Serbia
-
Dompé Farmaceutici S.p.ATerminated
-
Dompé Farmaceutici S.p.AWithdrawnType I DiabetesUnited States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireCompletedHealthyUnited States
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingAddiction | Methamphetamine-dependence | Addiction, Substance | Methamphetamine AbuseCanada
-
ShireCompletedAttention-Deficit Hyperactivity DisorderUnited States
-
University GhentShire; Fund for Scientific Research, Flanders, BelgiumWithdrawnAttention Deficit Hyperactivity DisorderBelgium
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom